@article {1949, title = {Effects of Pomegranate Extract Supplementation (Punica granatum L.) on Clinical Manifestations of Pulmonary Arterial Hypertension in Children with Acyanotic Congenital Heart Disease}, journal = {Pharmacognosy Journal}, volume = {14}, year = {2022}, month = {January 2023}, pages = {1061-1066}, type = {Research Article }, chapter = {1061}, abstract = {

Background: Pulmonary arterial hypertension (PAH) in congenital heart disease (CHD) mechanism includes vasoconstriction and vascular remodeling. In Indonesia, sildenafil as a vasodilator is the only standard treatment for PAH. Research on pomegranate extract showed its potential as an anti-inflammatory and anti-proliferative agent that could work synergically with sildenafil in reducing pulmonary arterial pressure (PAP) Objective: To investigate the effect of pomegranate supplementation in the clinical manifestation of PAH in children with acyanotic CHD. Methods: This study was a randomized controlled clinical trial that compared the clinical manifestation of PAH in children with acyanotic CHD who received standard therapy for PAH and pomegranate extract supplementation with the placebo group. Observations were carried out over three months, and pre-and post-test evaluations were conducted to assess changes in PAP, functional classification of PAH, body weight, systolic blood pressure, heart rate, respiratory rate, and oxygen saturation in both groups. Statistical analysis was undertaken using the Wilcoxon, Mann-Whitney, and Spearman correlation tests. Results: There was no significant difference in PAP reduction between the pomegranate and placebo groups (p = .44) and no significant difference in the functional classification of PAH in the placebo and pomegranate groups (p = .55). There was a considerable reduction in the respiratory rate in the pomegranate group (p = .017). Respiratory rate was positively correlated with the functional classification of PAH (p = .011). Conclusion: There was a significant reduction in the respiratory rate in the pomegranate group that correlated with the functional classification of PAH.

}, keywords = {Heart disease, Pomegranate, Pulmonary hypertension, Sildenafil.}, doi = {10.5530/pj.2022.14.210}, author = {Audylia Hartono and Mahrus A. Rahman and Budi Utomo} } @article {633, title = {Potential Effects of Pomegranate Juice in Attenuating LID in Mice Model of Parkinson Disease}, journal = {Pharmacognosy Journal}, volume = {10}, year = {2018}, month = {June 2018}, pages = {700-704}, type = {Original Article}, chapter = {700}, abstract = {

Purpose: Parkinson\’s disease (PD) is one of the most important neurodegenerative diseases, known with tremor, rigidity and bradykinesia resulted from chronic degeneration and death of sub thalamic nucleus (STN). According to the treatment benefits of levodopa on Parkinson, long-term levodopa administration causes some complications called levodopa-induced dyskinesia (LID) with poorly understood pathogenesis. Literature shows that polyphenol rich compound like pomegranate protect neurons of animals that are Parkinson induced, with some controversy. Objectives: In this study, the potential effects of pomegranate in attenuating LID in parkinsonian mice induced with 4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) were investigated. Materials: Mouse model of PD was induced by MPTP. To induce LID, valid PD mice were treated with levodopa (50 mg/kg, i.p) for 21 days. Then the effects of chronic co-administration of pomegranate juice (20 ml/kg) orally, with levodopa and continuing for another 20 days, evaluated. Behavioural tests were performed in all groups, every other day including: Abnormal involuntary movements (AIMs), cylinder and catatonia tests. Results: Levodopa in chronic administration induced dyskinesia that observed in AIMs and cylinder tests for 3 weeks when compared to untreated animals (P\<0.05 or 0.01) depending the time course). Besides, catatonia was recorded after two weeks and mounted time-dependently compared to control (P\<0.01). Chronic pomegranate co-administration improved AIMs scores for next 20 days (P\<0.01, in following days, compared to no-pomegranate treated group), attenuated cylinder scores and catatonia rates dramatically and time dependently (P\<0.01). Conclusion: Chronic pomegranate co-administration improved movements in all test results. It is then, concluded that pomegranate can be a good adjunct for attenuating LID and catatonia in mice.

}, keywords = {Levodopa-induced dyskinesia (LID), Mice, MPTP, Parkinson{\textquoteright}s disease, Pomegranate}, doi = {10.5530/pj.2018.4.116}, url = {http://fulltxt.org/article/654}, author = {Sarah Rezaee and Mahsa Hadipour Jahromy} }